

Date: March 13, 2026

BSE Limited
Floor 25, P. J. Towers
Dalal Street, Fort
Mumbai - 400 001

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra (E)
Mumbai - 400 051

Dear Sirs,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the 'SEBI Listing Regulations')

Pursuant to Regulation 30 of the SEBI Listing Regulations read with read with SEBI Master Circular No: HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 ('SEBI Circular'), we wish to inform you that the Company has entered into the Share Purchase Agreement with Remidex Pharma Private Limited ('Remidex') for acquisition of its 100% stake. After acquisition Remidex will become wholly owned subsidiary of the Company.

Relevant details prescribed under Regulation 30 of the SEBI Listing Regulations and SEBI Circular are enclosed as **Annexure-A** to this letter.

Date and time of occurrence of event is March 13, 2026 at 8:00 PM (IST).

We request you to take the same on record.

Thanking you,

Yours faithfully,
For Jubilant Ingrevia Limited

Deepanjali Gulati
Company Secretary

Encl.: As above

A Jubilant Bhartia Company

OUR VALUES



Jubilant Ingrevia Limited
1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantingrevia.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
Uttar Pradesh, India
CIN : L24299UP2019PLC122657

Annexure-A

Sr. No.	Particulars	Details
1.	Name of the target entity, details in brief such as size, turnover etc.	Remidex Pharma Private Limited ('Remidex'), incorporated on 15 th June 1981, at Bangalore, India is in the business of manufacturing and selling micronutrient premixes and nutraceuticals. Remidex is also a contract manufacturing organization for leading Indian and multinational pharmaceutical organizations. Turnover of Remidex during FY 24-25 was Rs. 24.27 Cr.
2.	Whether the acquisition falls within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	No
3.	Industry to which the entity being acquired belongs	Human Nutrition - Premix and Pharmaceutical manufacturing.
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	This acquisition will enable Jubilant Ingrevia to move forward in the value chain towards Premixes in Human Nutrition Space building upon its leadership position in Vitamins (Vitamin B3 & B4).
5.	Brief details of any governmental or regulatory approvals required for the acquisition	Not Required

A Jubilant Bhartia Company

OUR VALUES



Jubilant Ingrevia Limited

1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantingrevia.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
Uttar Pradesh, India
CIN : L24299UP2019PLC122657

Sr. No.	Particulars	Details
6.	Indicative time period for completion of the acquisition	30 days
7.	Nature of consideration - whether cash consideration or share swap and details of the same	Cash Consideration
8.	Cost of acquisition or the price at which the shares are acquired	Rs. 16.5 cr. subject to customary closing conditions
9.	Percentage of shareholding/ control acquired and/ or number of shares acquired;	100% Equity Shares.
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p>Remidex was incorporated in India on 15th June, 1981. It is one of the top players in the manufacture of multivitamin premixes for nutritional products and food products. It has a high-grade manufacturing facility in Bangalore with all key certifications e.g., WHO-GMP, FSSC, FSSAI etc. With a marquee customer base, strong innovation and quality control capability, Remidex is considered one of the leading player in Human Nutrition industry.</p> <p>Turnover of Remidex during last 3 years:</p> <p>FY 24-25: Rs. 24.27 Cr. FY 23-24: Rs. 31.15 Cr. FY 22-23: Rs. 30.51 Cr.</p>

A Jubilant Bhartia Company

OUR VALUES



Jubilant Ingrevia Limited

1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantingrevia.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
Uttar Pradesh, India
CIN : L24299UP2019PLC122657